g.tec medical engineering

Phase A — Understand the business

Lens 1 · Company Overview

g.tec medical engineering GmbH is a privately held neurotechnology company founded in 1999 in Graz, Austria as a spin-off of the Graz University of Technology (TU Graz), headquartered in Schiedlberg, Upper Austria, with branch offices in Graz, Barcelona (Spain) and New York (USA). It was founded by Dr. Christoph Guger and Günter Edlinger, who built one of the first real-time, commercial EEG-based brain–computer interface (BCI) systems while PhD students at TU Graz, and who have both been co-CEOs ever since. ~27 years under continuous founder control.

The business has two distinct engines, both built on the same core competence (acquiring and decoding scalp/cortical electrical brain signals in real time):

1. Research- and clinical-grade neurotech hardware + software sold B2B to universities, hospitals, neurosurgeons and labs worldwide. The flagship lines:

• Biosignal amplifiers — g.USBamp, g.HIamp (up to 256 channels), g.Nautilus (wireless EEG/fNIRS headset).
• High-density / invasive neurophysiology — g.Pangolin ("the world's first ultra-high-density electrode grid," up to 1,024 EEG channels from the human head) and cortiQ (real-time high-gamma functional brain mapping for epilepsy surgery / seizure localization).
• BCI applications — intendiX (P300 speller for locked-in / severe-motor-disability patients), mindBEAGLE (consciousness assessment for disorders-of-consciousness patients).
• Developer / education tier — Unicorn Hybrid Black 8-channel wireless EEG (~€1,089 / ~$1,100), Unicorn Education Kit, Core-4/Core-8.

1. recoveriX — a closed-loop BCI neurorehabilitation system (Motor Imagery EEG + Functional Electrical Stimulation + Virtual Reality feedback) for stroke, multiple sclerosis and Parkinson's motor recovery, launched 2016 and now distributed as a geographic franchise / clinic network.

Customers/suppliers/competitors. Customers = research universities (first BCI system sold to Oxford + a South Korean institute in 1999), hospitals/neurosurgery departments, plus (per the founder) automotive, aerospace, military and "tech giant" research buyers; recoveriX customers = franchise clinics treating private-pay rehab patients. Suppliers = standard electronics/sensor supply chain (amplifiers, electrodes, EEG caps/gel) — no disclosed single-source chokepoint. Competitors below (Lens 3).

"Contract structure." Two revenue shapes: (a) capital-equipment sales of amplifiers/headsets (one-time, plus consumables) — lumpy, project-driven; (b) recoveriX = recurring — a yearly system fee plus an 11%-of-turnover franchise fee plus consumables (EEG gel, FES electrodes). The recoveriX model is the strategically interesting one: it converts a hardware sale into an annuity.

customers.csv / segments.csv are empty in the research layer → all of the above is , not .

Lens 2 · Supply Chain

Names or it didn't happen — but for a private 60-person hardware shop the chain is short and largely undisclosed.

Upstream inputs g.tec End customer
───────────────────────────────── ─────────────────────────── ──────────────────────────
ADC / amplifier ICs, biopotential → g.tec designs + assembles → Research universities (Oxford,
front-ends, microcontrollers the amplifiers (g.USBamp, TU Graz, MIT/Harvard/Oxford
(generic semis — not disclosed) g.HIamp, g.Nautilus) and labs per its conference network)
 the g.Pangolin 1,024-ch grid
EEG electrodes, caps, conductive → in-house firmware + decoding → Hospitals / neurosurgery depts
gel, FES electrode pads software (intendiX, cortiQ, (cortiQ epilepsy mapping)
(consumables — recurring) recoveriX, Unicorn SDK)
 → recoveriX FRANCHISE CLINICS
VR headsets + FES stimulators → recoveriX = systems- (the de-facto distribution layer:
(integrated 3rd-party hardware integration of MI-BCI + FES Austria multi-city, Germany ~25
for the recoveriX bundle) + VR into a turnkey clinic planned centers via 4 partners,
 product Italy/NL/Finland/Spain/Portugal/
 Croatia/Slovenia, Canada/Mexico,
 Israel/Thailand/HK, Nigeria/SA)

Chokepoints / single-source. None publicly disclosed on the input side — the components (ADCs, electrodes, gel, VR/FES) are commodity-ish and multi-sourced. The real dependency is the franchise channel: recoveriX growth is gated by signing and ramping independent clinic operators, not by manufacturing. The other structural dependency is two people (the co-founders) — see Lens 9. supply-chain.md is missing from the KB → `` only; this lens is necessarily thinner than for a public hardware name with a 10-K supplier list.

Lens 3 · Competitive Advantages (moats)

g.tec's durable advantages are narrow but genuine for its niche:

• Incumbency + the research install base (the strongest moat). 27 years, 330+ peer-reviewed publications citing g.tec gear (incl. Nature, Frontiers), a recommended-citation list, and a first-mover history (first portable EEG amplifier 1999) make g.tec amplifiers a de-facto standard in academic BCI labs. MarketsandMarkets names G.Tech Medical Engineering (Austria) and Advanced Brain Monitoring (US) as the leading players in the BCI market — striking for a 60-person bootstrap. Switching cost in research is real: published methods, trained students, and validated pipelines lock to specific amplifiers.
• Ecosystem / mind-share engineering. The BR41N.IO hackathon series (since 2017, 400+ participants/event across Dublin, Linz, Graz, Valencia, Banff…) and the annual BCI Award seed the next generation of BCI researchers onto g.tec tooling, and the planned mega-conference ("world's largest BCI event," 140 lectures) is category-ownership marketing. This is a moat by community, not by patent.
• Vertical integration into therapy (recoveriX). Moving from selling amplifiers to owning a branded clinical protocol + franchise network is a higher-margin, recurring, harder-to-copy position than commodity EEG boxes.
• Bargaining power. Modest. Over component suppliers: low (small buyer of generic parts). Over customers: moderate in research (standard status) but weak vs. payers — recoveriX is largely private-pay because broad reimbursement isn't established (Lens 10/13). Against the well-capitalized frontier (Neuralink/Synchron/Precision) g.tec has near-zero capital power — it cannot out-spend them; it competes on a different axis (non-invasive, affordable, research/rehab) entirely.

positioning.md / bottlenecks.md missing → ``.

Lens 4 · Segments

No segment-level financials are published (private; segments.csv empty). Qualitatively the revenue splits into:

• Neurotech hardware + research software (amplifiers, g.Pangolin/cortiQ, Unicorn, intendiX/mindBEAGLE) — the legacy core; lumpy capital sales + consumables; the cash engine that funded everything.
• recoveriX neurorehab (system fees + 11% franchise turnover fee + consumables) — the growth + recurring segment; per-system economics: €180,000/yr turnover per recoveriX system (€80/hr therapy × 90 patients/yr; one therapist runs up to 3 systems simultaneously).
• Geography: Austria/Germany/EU core, with US (NY) and APAC/MEA franchise expansion.

Hard split by € is n/a — private, not disclosed. Total company revenue ~$7.7M (2026), ~60 employees (some sources 46–59), estimated valuation ~$24M. Trend: small, steady, profitable-bootstrap shape — not hypergrowth.

---

Phase B — Measure performance

Lens 5 · Earnings Result (private overlay → "Funding & valuation trajectory" + traction)

No earnings print exists. Substituting the +private lens:

• Funding trajectory — the defining fact. g.tec has raised only ~$2.0M in total external funding across ~19 "rounds" from ~2 investors, and that "funding" is dominated by EU research grants — e.g. €438,438 (AEGEUS EEG-ultrasound), €174,167 (disorders-of-consciousness diagnosis/rehab), €154,121 (magnetoelectric nanomaterials training), plus H2020 RecoveriX (CORDIS id 693928) and BeMAGIC/BETTER/BRAINGAIT/MOVEAGAIN projects. There is no venture round, no Series A/B, no priced equity raise of consequence. This is a bootstrapped, founder-owned, grant-supplemented company — it has funded 27 years of R&D out of product revenue + EU money, which is itself the headline.
• Revenue traction. ~$7.7M annual revenue (2026); ~60 staff implies $128k revenue/employee — modest, consistent with a hardware+services shop, not a software-margin business. Multi-year revenue history is n/a — not disclosed, but headcount growth is flat-to-slightly-negative (−1.6% YoY), i.e. steady-state, not scaling fast.
• Valuation. ~$24M est. — consistent with ~3× revenue for a profitable niche medtech. No primary-market round or secondary marks exist (the +private cap-table tell in Lens 7 is therefore absent, which is itself diagnostic — see below).
• Burn signals. None evident — a 27-year-old company on $2M lifetime external capital is self-sustaining/profitable by definition (you cannot survive 27 years burning on $2M). This is the inverse risk profile of the venture BCI cohort.

Lens 6 · Earnings Calls (private overlay → founder interviews / public posture)

No earnings calls. Reading the founder's public narrative (Guger interviews in CEO Weekly, The Arabian Mirror, Visionary CIOs, Enterprise World; the gtec.at "25 years" retrospectives) as the sentiment proxy:

• Consistent messaging: "NEVER STOP RECORDING" (the company tagline), 25-years-of-innovation framing, mission-led ("help patients move/communicate again"), academic-credibility-forward (publications, citation list, BCI Award).
• Recent emphasis shift (2024→2026): clear pivot from "we make research amplifiers" toward (a) recoveriX as a scalable clinical/franchise business and (b) invasive/high-density ECoG (g.Pangolin 1,024-channel, cortiQ for epilepsy surgery) — i.e. moving up the value chain into both therapy revenue and higher-resolution (closer to the invasive frontier) science. The mega-conference push reads as a category-ownership / brand-building posture rather than a capital-raising one.
• Tone: founder-stable, long-horizon, un-hyped. Notably absent: any "we're raising / going public / scaling to $X00M" venture language. The signal is lifestyle-of-the-mission durability, not a path-to-liquidity.

Lens 7 · Comps (private overlay → cap table & peer set)

Cap-table & secondary-marks read (the +private IPO-proximity tell): g.tec has essentially no venture cap table — no tier-1 VC, no crossover fund (Fidelity/T. Rowe/Coatue), no secondary market, no mutual-fund markups. By the skill's own logic, the absence of a crossover-fund entry is the signal: g.tec is not on an IPO trajectory. It is a founder-owned operating business. Multiples: n/a — private, not disclosed; ~$24M valuation is a single third-party estimate, not a transaction.

Lens 8 · Stock-Price Catalysts (no stock → value-inflection events instead)

No equity → no >5% price moves. The events that de-risk or re-rate the business (and would matter if it ever became tradeable, or to a category trade):

• recoveriX franchise signings — e.g. Germany's 4-partner / ~25-center agreement; APAC/MEA expansion. Each cohort of clinics is recurring-revenue accretive.
• Clinical-evidence prints — new RCTs/meta-analyses on BCI-FES stroke rehab (the category's efficacy debate, Lens 13). The April 2026 gait-rehab trial (ClinicalTrials.gov NCT07537530) is a live catalyst.
• High-density / invasive milestones — g.Pangolin 1,024-channel adoption + cortiQ epilepsy-surgery deployments at "leading hospitals".
• Reimbursement decisions — any payer/insurer coverage for BCI rehab would step-change recoveriX's TAM (currently private-pay-gated).
• Category re-rating — Neuralink/Synchron clinical wins lift all BCI mind-share; g.tec benefits as the non-invasive/affordable incumbent even without itself raising.

---

Phase C — Judge people & books

Lens 9 · Management

• Track record (quantified, qualitative — strong for the niche). Co-founders Christoph Guger (CEO) and Günter Edlinger built the first real-time commercial BCI as PhD students, then bootstrapped a category-leading neurotech firm over 27 years to ~$7.7M revenue, ~60 staff, 330+ citing publications, global offices, and a recurring-revenue rehab franchise — on ~$2M of external (mostly grant) money. That capital efficiency is exceptional. Guger personally is the public face (interviews, BCI Award, conferences).
• Tenure & skin in the game. ~27 years, both founders still co-CEO → maximal alignment and (almost certainly) majority/total insider ownership of a private GmbH. Insider-ownership exact % = n/a (private), but founder-run-since-1999 implies near-total control. This is the cleanest possible incentive alignment.
• Capital-allocation history. Disciplined and reinvestment-led: plowed product cash + EU grants into R&D (amplifiers → high-density ECoG → recoveriX), built an ecosystem (hackathons, awards, conference) rather than chasing dilutive growth capital. No evidence of value destruction; no buybacks/dividends data (private).
• Red flags (management). (1) Two-person key-man concentration — the entire 27-year arc rests on two founders; no disclosed deep bench or succession plan. (2) Promotional-content tilt — much of the "news" footprint is paid/placed founder-profile articles (CEO Weekly, Arabian Mirror, NY Weekly, Enterprise World, Visionary CIOs are pay-to-feature outlets) and self-published gtec.at posts; the "80,000-attendee, 100 elite professors" mega-conference claim is self-asserted, unverified marketing — discount it. (3) Mission-over-scale posture means limited urgency to professionalize/scale.
• Archetype: founder-operators / scientist-entrepreneurs running a durable lifestyle-and-mission business — not venture-backed empire-builders. For this stage and category that's a feature (survival, focus, alignment), but it caps the upside and the liquidity path.

Lens 10 · Forensic Red Flags

Forensic posture, constrained by zero audited financials.

• No financial statements to forensically test. Private GmbH; no income statement / balance sheet / cash-flow in the research layer or public domain. Standard forensic checks (rev-rec, receivables vs. revenue, SBC, goodwill, cash-vs-earnings divergence) are n/a — private, not disclosed. The one thing the numbers do tell us is positive: 27-year survival on ~$2M external capital ⇒ genuine operating profitability, the opposite of a going-concern flag.
• Business-model risks worth flagging (not accounting fraud, but quality-of-revenue):
• Franchise-revenue quality — recoveriX growth depends on independent operators succeeding; the €180k/system/yr economics are g.tec's own marketing math (90 patients × €80/hr), not audited clinic results. If clinics under-fill, franchise/turnover fees disappoint. Treat the per-system economics as a sales claim, not a fact.
• Clinical-claim aggressiveness — recoveriX marketing cites strong motor-recovery numbers (e.g. +4.68 FMA-UE; +0.19 m/s walking speed; benefit "30 years post-stroke"); the independent literature on BCI-FES rehab shows only moderate effect sizes with heterogeneous protocols and unresolved efficacy (Lens 13). Gap between marketing and consensus evidence = reputational/regulatory risk.
• Regulatory findings (required sub-section). Per regulatory/regulatory-findings.md (research-layer): g.tec has no SEC CIK (private, non-filer) → no EDGAR Litigation Releases or AAERs possible; 0 SEC findings. Non-SEC web search — "g.tec medical engineering" (FTC OR DOJ OR FDA OR consent decree OR settlement OR fine OR penalty) enforcement — returned no material enforcement actions, fines, or consent decrees. No 10-K Item 3 exists (private). Device-regulatory status is the one open gap: recoveriX/intendiX are CE-marked medical devices for the EU market (required to sell clinically in Europe; CE implied by EU distribution but the specific MDR class — likely IIa — was not confirmable in public sources), and no FDA 510(k) clearance for recoveriX was found in the FDA database via web search — consistent with one trial listing noting it as not currently an FDA-regulated device. Net: No material legal/enforcement findings — verified via SEC EDGAR EFTS (no CIK), web search, and absence of FDA actions as of 2026-06-23. CE/FDA device-class specifics unconfirmed (private-company disclosure gap), flagged as an open item, not a red flag.

---

Phase D — Project & stress-test

Lens 11 · Forward Projection (private overlay → IPO-readiness & path-to-tradeable)

No EPS model (private, no share count, no audited P&L → an EPS projection would be fabrication). Substituting the +private lens. No forecast.ts create (per --watchlist rules and the no-EPS reality).

• IPO-readiness: LOW (≈1–2 on the 1–5 readiness scale). g.tec is not in private-watch.json, and on the merits it sits at "early/growth," not "pre-IPO." The diagnostic milestones an S-1 would need are absent: no institutional venture round, no crossover-fund entry, no secondary market, founder-owned, ~$7.7M revenue (an order of magnitude below typical IPO scale), flat headcount. The skill's IPO-proximity tells all point away from tradeability.
• Path-to-tradeable — most likely outcomes (in order):

1. Stay private indefinitely (base case) — a durable, profitable, founder-run niche leader. No liquidity event. This is the rational expectation given 27 years of behavior.
2. Strategic acquisition — the realistic "exit": a larger medtech / neuro / rehab player (or a frontier BCI company wanting the non-invasive install base, the recoveriX channel, the g.Pangolin/cortiQ IP, and the 330-publication credibility) acquires g.tec. At ~$24M est. value it's an affordable bolt-on, not a mega-deal.
3. Distant/unlikely IPO — would require a venture-scale capital raise and a multi-year revenue step-change first; nothing signals this.

• Revenue trajectory: if recoveriX franchising compounds (Germany's ~25 centers + APAC/MEA) on top of a stable hardware base, mid-single-digit-to-low-teens % revenue growth is plausible — taking ~$7.7M toward ~$10–12M over a few years. Not a tradeable forecast.
• private-watch.json write-back: NOT performed — wave boundary forbids editing the watchlist/private-watch in this unattended run. (If Connor wants g.tec tracked as a category tell, add it manually at readiness 1–2, beat bci, dossier = this file.)

Lens 12 · Bull vs Bear

Bull case. g.tec is the profitable, un-hyped grandfather of non-invasive BCI — the company that quietly won the research-EEG install base (de-facto standard, 330+ publications, named a category leader alongside Advanced Brain Monitoring) while everyone watched Neuralink. It has done what no venture BCI has: 27 years of survival and profitability on ~$2M of external money. It's now layering a recurring, high-margin, capital-light recoveriX franchise annuity (€180k/yr/system economics) on top of that base, and pushing into higher-resolution invasive ECoG (g.Pangolin 1,024-ch, cortiQ epilepsy mapping) — so it has optionality on both the affordable-rehab market and the frontier-science market. As the non-invasive BCI category (61.7% of a ~$1.3–2.9B market, growing ~15% CAGR ) inflates on Neuralink/Synchron hype, g.tec is the safe, real-revenue, immediately-deployable incumbent that hospitals and labs actually buy today. Best outcome: an acquirer pays a strategic premium for the install base + channel + IP.

Bear case (3 permanent-impairment risks). (1) Structurally sub-scale & capital-starved — on $2M lifetime funding it cannot fund the scale-up, sales force, or reimbursement campaigns that would turn recoveriX into a mass therapy; a well-capitalized rival (or a deep-pocketed frontier BCI moving down-market) could out-invest the non-invasive/rehab opportunity and strand g.tec at ~$8–12M revenue forever. (2) The clinical-evidence ceiling — non-invasive EEG is fundamentally signal-quality-limited, and the independent literature rates BCI-FES rehab only moderately effective with unresolved, heterogeneous evidence; if a definitive trial underwhelms or payers refuse coverage, recoveriX stays a private-pay niche. (3) Two-founder key-man risk — the entire enterprise is two scientists who've run it since 1999; no disclosed succession.

Pre-mortem (18 months out, thesis broke): recoveriX franchise clinics under-fill (the €180k/system math proves optimistic), the German ~25-center ramp stalls, a high-profile BCI-rehab RCT prints null, payers decline reimbursement, AND a frontier player (or a funded Bitbrain/competitor) bundles a slicker non-invasive rehab offering — leaving g.tec as a respected-but-stagnant research-hardware vendor while the narrative and capital concentrate on invasive BCI.

Is the (implied ~$24M) valuation too high? No — ~3× revenue for a 27-year profitable, category-leading niche medtech with a recurring-revenue franchise layer looks conservative-to-fair. The risk isn't overvaluation; it's illiquidity + a capped scaling path.

Contrarian view (what the market refuses to see): Everyone equates "BCI" with invasive implants and venture rockets. The market ignores that the company already named a leading BCI player is a profitable Austrian bootstrap with real customers and a franchise annuity — and that non-invasive holds the majority of the actual BCI market today. g.tec is the boring, real, cash-flowing reality under the implant hype. The contrarian read: the category is investable; g.tec the equity is simply not available — so the trade is to use g.tec as the proof that non-invasive BCI is a real, monetizable market and express it through whatever becomes tradeable.

Lens 13 · Devil's Advocate (short-seller)

Dismantling the bull case (acknowledging there's no stock to short — this stress-tests the thesis):

• Where revenue concentrates & what breaks it: revenue leans on (a) lumpy research-hardware capital sales (vulnerable to academic-funding cycles and to Brain Products / ANT Neuro / Bitbrain taking share) and (b) a franchise model whose unit economics are g.tec's own unaudited marketing claims. If clinics don't hit 90 patients/yr at €80/hr, the 11% turnover fee evaporates — and g.tec has no public clinic-level utilization data to prove the model works at scale.
• Why the moat is weaker than bulls think: the "research-standard" moat is erodable — Bitbrain (AI-forward, B2B), Brain Products, and open hardware (OpenBCI) chip at the amplifier business; in consumer/dev EEG, Emotiv/Muse/NeuroSky already out-sell Unicorn on volume. The therapy moat depends on clinical evidence that consensus calls only "moderate" and "debated," not the strong claims in recoveriX marketing.
• Most dangerous competitor bulls underestimate: not Neuralink — it's a well-funded non-invasive/AI neurotech (Bitbrain-type) or a large rehab-device incumbent that combines capital + reimbursement expertise + a slicker product to commoditize BCI rehab. g.tec's ~$2M war chest can't answer that.
• Worst capital-allocation / governance concerns: heavy reliance on EU grants (lumpy, non-dilutive but finite and bureaucratic) and a marketing footprint built on pay-to-feature founder profiles + self-asserted superlatives (the "80,000-attendee" conference) — a promotional tell that warrants discounting management's claims.
• What must hold for the (implied) value: that recoveriX franchising actually compounds AND that non-invasive BCI rehab earns clinical/payer legitimacy. If recoveriX growth disappoints 20–30%, g.tec reverts to a flat ~$8M research-hardware vendor — fine as a business, uninteresting as a growth/IPO story, and worth less than the ~$24M tag.
• Single permanent-impairment scenario: a definitive negative RCT on BCI-FES stroke rehab (or a blanket payer non-coverage decision) that brands the whole recoveriX category as unproven — plausibility moderate; it would kneecap the one part of g.tec with real upside.

Lens 14 · Management Questions (ordered by information value)

1. recoveriX unit economics — show the real data: across your operating franchise clinics, what is the actual distribution of patients/year and utilization vs. the €180k/system marketing figure, and what % of clinics are profitable after 24 months?
2. Reimbursement: in which markets (if any) is recoveriX therapy reimbursed by public/private payers, and what is the concrete path to broader coverage?
3. Regulatory status, precisely: what is recoveriX's EU MDR device class and CE certificate status, and do you intend an FDA 510(k)/De Novo for the US — on what timeline?
4. Capital strategy: after 27 years bootstrapped on ~$2M, would you take outside growth capital to scale recoveriX — or is staying founder-owned a hard constraint? What would change your mind?
5. Succession / key-man: the company has been you two since 1999 — what is the succession plan, and who runs g.tec if both founders step back?
6. Clinical evidence: independent meta-analyses rate BCI-FES rehab only "moderately" effective with heterogeneous protocols — what new, independent, randomized evidence (e.g. NCT07537530) will you point to, and when?
7. Competitive defense: how do you defend the research-amplifier base against Brain Products, ANT Neuro, Bitbrain, and open-source hardware over the next five years?
8. Invasive bet: what is the commercial thesis for g.Pangolin (1,024-ch) and cortiQ — is invasive/ECoG a real revenue line or a credibility/research halo?
9. Frontier exposure: as Neuralink/Synchron raise BCI's profile, do you see them as tailwind (category lift) or eventual down-market threat to non-invasive?
10. Revenue mix: what is the actual split today between hardware sales vs. recoveriX recurring, and where is each headed?
11. Geographic concentration: how dependent is revenue on Austria/Germany/EU, and what's the realistic US/APAC contribution timeline?
12. Grant dependency: how much of R&D is EU-grant-funded, and how exposed are you if that funding tightens?
13. Franchise quality control: how do you ensure clinical outcomes and brand integrity across independent franchise operators worldwide?
14. Exit: under what circumstances would you sell g.tec, and to whom would it be most valuable?
15. The 10-year vision: is g.tec aiming to be a durable profitable niche leader, or to become the non-invasive BCI platform at scale — and what does each path require?

---